Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers
From MaRDI portal
(Redirected from Publication:1790751)
Abstract: Although optimal control theory has been used for the theoretical study of anti-cancerous drugs scheduling optimization, with the aim of reducing the primary tumor volume, the effect on metastases is often ignored. Here, we use a previously published model for metastatic development to define an optimal control problem at the scale of the entire organism of the patient. In silico study of the impact of different scheduling strategies for anti-angiogenic and cytotoxic agents (either in monotherapy or in combination) is performed to compare a low-dose, continuous, metronomic administration scheme with a more classical maximum tolerated dose schedule. Simulation results reveal differences between primary tumor reduction and control of metastases but overall suggest use of the metronomic protocol.
Recommendations
- Evaluating the efficacies of maximum tolerated dose and metronomic chemotherapies: a mathematical approach
- A review of optimal chemotherapy protocols: from MTD towards metronomic therapy
- A mathematical justification for metronomic chemotherapy in oncology
- Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis
- Optimizing chemoradiotherapy to target metastatic disease and tumor growth
- Optimal scheduling of radiotherapy and angiogenic inhibitors
- Optimisation of time-scheduled regimen for anti-cancer drug infusion
- On drug resistance and metronomic chemotherapy: a mathematical modeling and optimal control approach
- Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent
Cites work
- scientific article; zbMATH DE number 4112436 (Why is no real title available?)
- A history of the study of solid tumour growth: the contribution of mathematical modelling
- A model describing the growth and the size distribution of multiple metastatic tumors
- A model for the resistance of tumor cells to cancer chemotherapeutic agents
- A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology
- An age-and-cyclin-structured cell population model for healthy and tumoral tissues
- An elementary approach to modeling drug resistance in cancer
- AntiAngiogenic Therapy in Cancer Treatment as an Optimal Control Problem
- Chemotherapy of vascularised tumours: role of vessel density and the effect of vascular ``pruning
- Circadian rhythm and cell population growth
- Drug resistance in cancer chemotherapy as an optimal control problem
- Mathematical analysis of a two-dimensional population model of metastatic growth including angiogenesis
- Mathematical and numerical analysis for a model of growing metastatic tumors
- Mathematical and numerical analysis of a model for anti-angiogenic therapy in metastatic cancers
- Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis
- Modeling the impact of anticancer agents on metastatic spreading
- On optimal delivery of combination therapy for tumors
- Optimal scheduling of radiotherapy and angiogenic inhibitors
- Realizable protocols for optimal administration of drugs in mathematical models for anti-angiogenic treatment
- Role of optimal control theory in cancer chemotherapy
- Scheduling of angiogenic inhibitors for Gompertzian and logistic tumor growth models
- Synchronisation and control of proliferation in cycling cell population models with age structure
- The influence of PK/PD on the structure of optimal controls in cancer chemotherapy models
- Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999)
Cited in
(22)- PATHO-PHYSIOLOGICALLY BASED LOGISTICS FOR TREATMENT OF CANCER
- Dynamical properties of a minimally parameterized mathematical model for metronomic chemotherapy
- Optimal control of cytotoxic and antiangiogenic therapies on prostate cancer growth
- A mathematical model to study low-dose metronomic scheduling for chemotherapy
- Dynamics and control of a mathematical model for metronomic chemotherapy
- A mathematical model of low grade gliomas treated with temozolomide and its therapeutical implications
- Evaluating the efficacies of maximum tolerated dose and metronomic chemotherapies: a mathematical approach
- Understanding the antiangiogenic effect of metronomic chemotherapy through a simple mathematical model
- Optimizing chemoradiotherapy to target metastatic disease and tumor growth
- Understanding avascular tumor growth and drug interactions through numerical analysis: a finite element method approach
- Numerical optimal control of a size-structured PDE model for metastatic cancer treatment
- Why is evolution important in cancer and what mathematics should be used to treat cancer? Focus on drug resistance
- Optimization of an \textit{in vitro} chemotherapy to avoid resistant tumours
- Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis
- Limiting the development of anti-cancer drug resistance in a spatial model of micrometastases
- Mathematical analysis and simulation study of a phase-field model of prostate cancer growth with chemotherapy and antiangiogenic therapy effects
- Optimal control of cancer chemotherapy with delays and state constraints
- Employing nullclines to balance treatment efficacy and neurotoxicity for sustained tumor control
- Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer
- Asymptotic analysis and optimal control of an integro-differential system modelling healthy and cancer cells exposed to chemotherapy
- Game theory for managing evolving systems: challenges and opportunities of including vector-valued strategies and life-history traits
- Practically scheduling hormone therapy for prostate cancer using a mathematical model
This page was built for publication: Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q1790751)
